in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Amgen to acquire Onyx Pharmaceuticals for $10.4 billion
8:55 AM MDT | August 26, 2013 | Natasha Alperowicz
Amgen (Thousand Oaks, CA), the world’s largest independent biotechnology company; and Onyx Pharmaceuticals announced on Sunday that their boards of directors have unanimously approved a transaction for Amgen to acquire all of the outstanding shares of Onyx for $125/share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Onyx has an...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee